On June 19th Vaccentis held a scientific advisory board with leading clinical experts in urology, oncology, pathology and pharmacology from Germany and Austria in Vienna to discuss the status and clinical development for their autologous tumour vaccine VCC-001.
The core statements of the advisory board were:
- VCC-001 represents a potential treatment option for pT3 patients (intermediate to high risk) in the adjuvant clear cell Renal cell cancer (ccRCC)
- VCC-001 could be a promising option in the adjuvant monotherapy setting, due to its favorable safety profile
- Potential patient profiles and clinical trial designs (Phase 2b and Phase 3) for VCC-001 were discussed and aligned